Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB completes systemic lupus erythematosus study

UCB completes systemic lupus erythematosus study

28th August 2009

UCB and Immunomedics have announced positive results from a clinical trial comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, which is also known as lupus).

It discovered that, by week 12 of the study, treatment advantage of epratuzumab over a placebo therapy reached 24.9 per cent.

The combined index endpoint was the primary efficacy measure, encompassing various indices of SLE disease activity. It used the British Isles Lupus Assessment Group’s measurement system as a guideline for improvement.

Chief executive of UCB Roch Doliveux stated: “Epratuzumab is the most advanced pipeline programme in UCB’s immunology disease portfolio and the positive results are significant for UCB as we continue to move our antibody-based programmes ahead.”

In other UCB news this week, the organisation revealed that intends to expand its joint operations with Novartis in Germany following the signing of a licensing agreement for cardiovascular and diabetes products in the country.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.